DB15858InvestigationalVaccines
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it... Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals.
- Code names
- KBP-COVID-19
What you can answer from here — as of April 23, 2025
Which companies are running trials of KBP-COVID-19, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account